Genzyme in the UK

Company Info

Sanofi Genzyme launches new UK nurse education programme in multiple sclerosis to help improve patient care and service delivery

Date: May 26, 2016

Oxford, UK. ­– Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the launch of OptiMiSe, a new education programme for multiple sclerosis (MS) specialist nurses in the UK that supports patient-centric care and changes in clinical practice for improved patient outcomes.

More than 100,000 people in the UK have MS1. MS is a complex condition in which the effects of the disease, its course and response to treatment differ with each person; meaning decisions must be made and care must be provided on a patient-by-patient basis. In order to cope with increasing complexity, both in terms of MS patient needs and system infrastructure, nurses who care for people with MS must be highly skilled, up-to-date on MS care developments and able to navigate a resource-constrained NHS.

Developed by an expert nurse-led steering committee, OptiMiSe will be carried out through face-to-face meetings as well as a web-based platform. It supports nurses in providing the highest-quality care to people affected by MS, as well as in the leading and managing of efficient service delivery.

“The programme is rooted in a unique combination of skills transfer, knowledge-share and thinking to tackle some of the barriers MS nurses face in their daily practice,” said Nicki Abel, Chair of the Expert Steering Committee of the OptiMiSe programme and MS specialist nurse at the Queen Elizabeth Hospital Birmingham. “The way in which we approached the programme and are conducting the training makes it fundamentally different from other education programmes, as it is structured around each nurse’s personal objectives, which encourages active participation, autonomous learning and passion for driving change and the process of learning.”

“Findings from research we conducted last year revealed the need for nurse education that zooms in on the delivery of MS care today and in the future, ultimately improving the experience patients have,” commented Peter Kuiper, General Manager UK & Ireland at Sanofi Genzyme. “Sanofi Genzyme recognises the important role nurses play in the care of people with MS and is really proud to support this initiative.”

The programme has already been piloted successfully through its Royal College of Nursing accredited London and York courses. It is supported by a medical education agency and organised and funded by Sanofi Genzyme.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Genzyme® is a registered trademark of Genzyme Corporation. Sanofi® is a registered trademark of Sanofi. All rights reserved.

References

  • 1MS Society. About MS. https://www.mssociety.org.uk/what-is-ms/information-about-ms/about-ms?utm_source=what-is-ms&utm_medium=link&utm_campaign=Landing-page-analysis&utm_content=about-ms. Accessed May 2016.

Contacts:
Media Relations
Stefanie Holman
Sanofi Genzyme UK & Ireland
Tel.: 01865 405 200 or 07740 935 273
stefanie.holman@sanofi.com

Reshma Parmar
Red Consultancy
Tel.: 0207 025 6585 or 07545 933 689
reshma.parmar@redconsultancy.com

GZUK.MS.16.05.0420a
Date of Preparation: May 2016

Highlight

  • Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

    Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. Read the full corporate press release.

Contact Info:

Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Tel: +01865 405200
Fax: +01865 774172
Email

Contact Info:

Genzyme Ltd, Haverhill Operations
12 Rookwood Way
Haverhill
Suffolk
CB9 8PU
Tel: +01440 703522
Fax: +01440 716269

'